Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Franklin

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Clinical and Experimental Gastroenterology|April 5, 2016
Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinenceHoward Franklin, Andrew C Barrett, Ray Wolf
Clinical Therapeutics|July 15, 2020
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or OlderStacy B Menees, Howard Franklin, William D Chey
Clinical Therapeutics|January 28, 2022
The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III TrialsBaharak Moshiree, Philip Schoenfeld, Howard Franklin, et al.
Journal of Clinical Gastroenterology|May 24, 2021
An Open-label, Multicenter Study to Assess the Efficacy and Safety of a Novel Probiotic Blend in Patients With Functional Gastrointestinal SymptomsLucinda A Harris, Brooks D Cash, Karim Moftah, et al.
The Oncologist|December 15, 2025
Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapyManuel Modiano, Shanta Chawla, Jeffrey L Vacirca, et al.
The American Journal of Gastroenterology|July 18, 2023
P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 StudyJimin Lee, Robert Lester, Terry O'Reilly, et al.
Clinical and Translational Gastroenterology|January 16, 2015
Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal IncontinenceJaime E Sanchez, Darren M Brenner, Howard Franklin, et al.
Clinical Pharmacology in Drug Development|January 28, 2023
A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy VolunteersJimin Lee, Robert Lester, Terry O'Reilly, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Clinical and Experimental Gastroenterology|April 5, 2016
Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinenceHoward Franklin, Andrew C Barrett, Ray Wolf
Clinical Therapeutics|July 15, 2020
Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or OlderStacy B Menees, Howard Franklin, William D Chey
Clinical Therapeutics|January 28, 2022
The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III TrialsBaharak Moshiree, Philip Schoenfeld, Howard Franklin, et al.
Journal of Clinical Gastroenterology|May 24, 2021
An Open-label, Multicenter Study to Assess the Efficacy and Safety of a Novel Probiotic Blend in Patients With Functional Gastrointestinal SymptomsLucinda A Harris, Brooks D Cash, Karim Moftah, et al.
The Oncologist|December 15, 2025
Safety and efficacy of same-day administration of eflapegrastim in patients with early-stage breast cancer receiving chemotherapyManuel Modiano, Shanta Chawla, Jeffrey L Vacirca, et al.
The American Journal of Gastroenterology|July 18, 2023
P029 Pharmacokinetic/Pharmacodynamic Analysis of Amiselimod, a Selective Sphingosine 1-Phosphate Receptor Modulator, in Healthy Subjects: Results From a Phase 1 StudyJimin Lee, Robert Lester, Terry O'Reilly, et al.
Clinical and Translational Gastroenterology|January 16, 2015
Validity of the ≥50% Response Threshold in Treatment With NASHA/Dx Injection Therapy for Fecal IncontinenceJaime E Sanchez, Darren M Brenner, Howard Franklin, et al.
Clinical Pharmacology in Drug Development|January 28, 2023
A Randomized, Double-Blind, Parallel Design Thorough QT Study With a Nested Crossover to Compare the Cardiac Safety of Amiselimod With Placebo and Positive Control in Healthy VolunteersJimin Lee, Robert Lester, Terry O'Reilly, et al.
Pageof 1